Alzheimer's Disease News and Research

RSS

Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.

Legislation grants improve research and employment initiatives in Indiana University medical campus

Indiana University School of Medicine scientists have received more than $12 million in grants funded by the federal economic stimulus legislation, funding that has bolstered both research initiatives and research employment on the medical center campus.

16 Sep 2009

Youthful Aging celebrates 15th anniversary

A most unusual home health care firm is marking its 15th anniversary of helping seniors do more than they think they can do.

16 Sep 2009

USPTO grants a provisional patent to INVENT Pharmaceuticals' Alzheimer’s drug

American Diversified Holdings Corporation (Pink Sheets: ADHC) Strategic Alliance partner INVENT Pharmaceuticals, Inc. announced today that the U.S. Patent and Trademark Office has granted its provisional patent application US 61/271,720 on novel drug candidates for the treatment of Alzheimer’s disease and age-related cognitive and memory impairment.

16 Sep 2009

Study reveals effectiveness of cognitive testing by telephone in elderly individuals

Cognitive testing by telephone in elderly individuals is generally as effective as in-person testing, according to a new study by Effie M. Mitsis, PhD, Assistant Professor of Psychiatry at Mount Sinai School of Medicine and part of Mount Sinai's Alzheimer's Disease Research Center. The study will appear in the International Journal of Geriatric Psychiatry.

16 Sep 2009

Findings could lead to new neurological treatments

The power of the imagination is well-known: it's no surprise that scary music is scarier with your eyes closed. But now neuroscientist and psychiatrist Prof. Talma Hendler of Tel Aviv University's Functional Brain Center says that this phenomenon may open the door to a new way of treating people with Alzheimer's, Parkinson's and other neurological diseases.

16 Sep 2009

Researchers analyze how genome influences human health

Two recent studies by Dartmouth researchers use individual genetic data to reveal the powers and limits of our current understanding of how the genome influences human health and what genes can reveal about the ancestry of the people of New Hampshire.

15 Sep 2009

iMedicor and Transgenomic to develop an educational marketing program for NuroPro

iMedicor and Transgenomic today announced that they have signed an agreement to develop an educational marketing program for NuroPro, Transgenomic’s diagnostic tests for Alzheimer’s and Parkinson’s disease.

15 Sep 2009

Elan rectifies Tysabri Collaboration Agreement breach

Elan Corporation, plc (NYSE: ELN) today announced that it has cured an unintended breach of its Tysabri Collaboration Agreement with Biogen that had been identified by the United States District Court for the Southern District of New York.

15 Sep 2009

Researchers study the degree of verbal impairment in AD patients

A postgraduate researcher at the University of Hertfordshire has found that Alzheimer's Disease (AD) results in greater language impairments in more highly-educated than less learned patients.

15 Sep 2009

Celebrity supports Alzheimer's Association

National Football League (NFL) wide receiver for the Buffalo Bills, Terrell Owens, will support the Alzheimer's Association this fall by having his own team for Memory Walk(R).

15 Sep 2009

New book on human genetics helps to unravel complex human diseases

Many human diseases-including Alzheimer's disease, schizophrenia, cancer, and cardiovascular disease-are caused by multiple genetic variants and the interaction of those variants with the environment. Because such diseases lack a clear-cut inheritance pattern, sophisticated technological approaches and statistical analyses are required to determine their underlying cause.

15 Sep 2009

Outreach and Registry Program to help combat and treat Alzheimer's disease

Today Senator Jay Rockefeller announced an unprecedented and powerful partnership to help combat and treat Alzheimer's disease in West Virginia.

15 Sep 2009

Mild cognitive impairment is a risk factor for dementia

Among individuals with mild cognitive impairment, often considered a transitional state between normal cognitive function and Alzheimer's dementia, those who have more difficulties performing routine activities appear more likely to progress quickly to dementia, according to a report in the September issue of Archives of Neurology, one of the JAMA/Archives journals.

15 Sep 2009

New protein substance could be used to diagnose Alzheimer's disease

Gothenburg researchers have discovered a previously unknown substance in spinal fluid that can be used to diagnose Alzheimer's disease. The findings, described in a thesis from the Sahlgrenska Academy at the University of Gothenburg, Sweden, will also be useful in research on new medications.

15 Sep 2009

Vivakor completes third-party validation testing of its VivaBlend nutraceutical product

Vivakor™, Inc. (OTCBB: VIVK) today announced the results of independent, third-party validation testing of its VivaBlend™ nutraceutical product. VivaBlend is a powerful extract developed by the scientists at Vivakor and is derived from over 18 highly bioactive fruits, vegetables and legumes. Through a proprietary formulation and extraction process, Vivakor scientists have maximized the health benefits of VivaBlend by creating an optimum blend of super-antioxidants and powerful plant phenolics and flavonoids.

14 Sep 2009

Phase IIa clinical data of EHT 0202 released

Top-line Phase IIa clinical data released today demonstrate that EHT 0202, ExonHit’s lead candidate for the treatment of Alzheimer’s disease, is safe and generally well tolerated in patients and that it could potentially enhance cognition in Alzheimer’s disease patients.

14 Sep 2009

U.S. Department of Justice awards grant to Project Lifesaver International

Project Lifesaver International, a non-profit organization that helps rescue citizens who are prone to wander due to Alzheimer's disease, autism, and other cognitive disorders, received notification of federal assistance yesterday.

14 Sep 2009

Improved-resolution views of a zinc transporter protein deciphered

New, improved-resolution views of a zinc transporter protein deciphered at the U.S. Department of Energy's Brookhaven National Laboratory provide not just a structure but also a suggested mechanism for how cells sense and regulate zinc, an element that is essential for life, but which must be kept at a steady state to avoid problems like seizures, diabetes, and possibly Alzheimer's disease.

14 Sep 2009

Scientific program to treat and prevent mental disorders

Mental disorders are a global problem and represent one of the biggest challenges for health care systems. In the world, there are some 500 million people suffering from mental disorders, and in the European Union, mental disorders range as one of the leading causes of disease burden.

14 Sep 2009

FDA accepts Merz Pharmaceuticals' premarket approval application for Belotero Balance

Merz Pharmaceuticals, LLC, a leading specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Merz's premarket approval (PMA) application for Belotero(R) Balance.

11 Sep 2009